Drugs approved for the treatment of multiple sclerosis: review of their safety profile-Reference-Cited by-同舟云学术

Drugs approved for the treatment of multiple sclerosis: review of their safety profile

Published:2017-10-12 Issue:12 Volume:16 Page:1359-1371
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Auricchio Fabiana¹^ORCID,Scavone Cristina¹,Cimmaruta Daniela¹,Di Mauro Gabriella¹,Capuano Annalisa¹,Sportiello Liberata¹,Rafaniello Concetta¹

Affiliation:

1. Department of Experimental Medicine, Section of Pharmacology “L. Donatelli”, School of Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2017.1388371

Reference134 articles.

1. Multiple Sclerosis: An Immune or Neurodegenerative Disorder?

2. Renin-angiotensin system gene polymorphisms as risk factors for multiple sclerosis

3. The Accuracy of Prevalence Rates of Multiple Sclerosis: A Critical Review

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hypogammaglobulinemia in patients with multiple sclerosis receiving disease modifying therapies: disproportionality analysis using the EudraVigilance database;Expert Opinion on Drug Safety;2025-04-23

2. Biological activities of astaxanthin in the treatment of neurodegenerative diseases;Neurodegenerative Disease Management;2024-11

3. Comparison of injective related reactions following ofatumumab and ocrelizumab in patients with multiple sclerosis: data from the European spontaneous reporting system;Frontiers in Neurology;2024-06-27

4. Disease-modifying therapies and hematological disorders: a systematic review of case reports and case series;Frontiers in Neurology;2024-06-18

5. Clinical efficacy of anti-CD20 antibodies in autoimmune diseases;Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal;2024